Log in
Sign up
Nurix

Nurix

A company developing protein homeostasis therapies for oncology, immunology, and inflammation cases

OverviewStructured DataIssuesContributorsActivity
Contents

Nurix Therapeutics is a biopharmaceutical company that focuses on discovering, developing and commercializing small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. Nurix Therapeutics discovers drugs that harness the body’s natural process to control protein levels.

Nutrix leverages its extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, to build DELigase, which is an integrated discovery platform for identifying and advancing novel drug candidates targeting E3 ligases, a wide class of enzymes that can modulate proteins within the cell.

Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system, to selectively decrease or increase cellular protein levels.

The wholly owned pipeline of Nutrix comprises of targeted protein degraders of Bruton’s tyrosine kinase, is a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, which is an E3 ligase that regulates T cell activation.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

nurixtx.com
nurix-inc.com
Is a
Company
Company
Organization
Organization

Company attributes

Industry
Engineering
Engineering
-1
Therapeutics
Therapeutics
Biomedical engineering
Biomedical engineering
Technology
Technology
Cancer
Cancer
Oncology
Oncology
Biology
Biology
...
Location
San Francisco
San Francisco
-1
CEO
‌
Arthur T. Sands
Founder
‌
Arthur Weiss
‌
John Kuriyan
‌
Michael Rape
AngelList URL
angel.co/nurix
Pitchbook URL
pitchbook.com/profiles.../60529-69
Legal Name
Nurix Therapeutics, Inc.-1
Number of Employees (Ranges)
51 – 200
Full Address
1700 Owens Street, Suite 205 San Francisco, CA 94158, USA-1
Investors
‌
The Column
Third Rock Ventures
Third Rock Ventures
The Column Group
The Column Group
Founded Date
2012
Email Address
ir@nurixtx.com-1
info@nurix-inc.com-1
Phone Number
+14156605320-1
Fax Number
415-525-4200-1
Total Funding Amount (USD)
28,200,000
Latest Funding Round Date
May 2014
Exchange
Nasdaq
Nasdaq
-1
Latest Funding Type
Series B round
Series B round
Wellfound ID
nurix
Country
United States
United States

Other attributes

Company Operating Status
Active
Ticker Symbol
NRIX-1
Wikidata ID
Q106411724

Find more companies like Nurix

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
Company
HomePress & MediaBlogCareers
We're hiring
Products
Knowledge GraphQuery ToolData RequestsKnowledge StorageAPIPricingEnterpriseChatGPT Plugin
Legal
Terms of ServiceEnterprise Terms of ServicePrivacy Policy
Help
Help centerAPI DocumentationContact Us
By using this site, you agree to our Terms of Service.